JULY 2021 - FINEXSI ISSUED ITS REPORT AS INDEPENDENT EXPERT IN CONNECTION WITH THE PROPOSED PUBLIC BUY-OUT OFFER FOLLOWED BY A SQUEEZE-OUT (OPR-RO) INITIATED BY CALLIDITAS THERAPEUTICS AB FOR THE SHARES OF GENKYOTEX S.A.

JULY 2021 – FINEXSI ISSUED ITS REPORT AS INDEPENDENT EXPERT IN CONNECTION WITH THE PROPOSED PUBLIC BUY-OUT OFFER FOLLOWED BY A SQUEEZE-OUT (OPR-RO) INITIATED BY CALLIDITAS THERAPEUTICS AB FOR THE SHARES OF GENKYOTEX S.A.

Following off-market block purchases, a simplified tender offer and the subscription to a capital increase, CALLIDITAS THERAPEUTICS AB held 90.3% … Continue reading JULY 2021 – FINEXSI ISSUED ITS REPORT AS INDEPENDENT EXPERT IN CONNECTION WITH THE PROPOSED PUBLIC BUY-OUT OFFER FOLLOWED BY A SQUEEZE-OUT (OPR-RO) INITIATED BY CALLIDITAS THERAPEUTICS AB FOR THE SHARES OF GENKYOTEX S.A.